BACKGROUND: Eicosapentaenoic acid (EPA) supplementation is an effective treatment option in major depressive disorder (MDD) associated with chronic low-grade inflammation. EPA is the precursor of specialized pro-resolving lipid mediators (SPMs) termed resolvins (Rv), that serve important roles in the resolution of inflammation. The objective of this study was to assess the effects of different doses of EPA on plasma concentrations of EPA metabolites and SPMs in MDD patients. METHODS: In a 2-site study, 61 MDD patients with body mass index >25 kg/m2 and serum high-sensitivity C-reactive protein ≥3 μg/mL were enrolled in a 12-week randomized trial comparing EPA 1, 2, and 4 g/d to placebo. Plasma EPA (mol%) and SPMs (pg/mL) were measured in 42 study completers at baseline and at the end of treatment by liquid chromatography/mass spectrometry. RESULTS: Plasma EPA and SPM concentrations did not change in the placebo group during 12 weeks of treatment. Plasma EPA and EPA-derived metabolites increased significantly and dose-dependently in all EPA supplementation arms. The increase in 18-hydroxyeicosapentaenoic acid (18-HEPE), the precursor of RvE1-3, was significantly greater with the 4 g/d EPA dose than the other doses from week 4 to 12. RvE1 was undetected in all treatment groups, while RvE2 was detected in half of the subjects both at baseline and after treatment, with dose-dependent increases. RvE3 was detected only after supplementation, dose-dependently. A significant reduction in plasma arachidonic acid (AA), relative to baseline, was observed in all EPA arms. This was in contrast with an increase in AA-derived SPM lipoxin B4 (LXB4) in the 4 g/d arm. CONCLUSIONS: Our results show a robust effect of EPA 4 g/d supplementation in increasing plasma EPA and 18-HEPE levels, associated with improved conversion to RvE2-3, and LXB4 levels.
BACKGROUND: Eicosapentaenoic acid (EPA) supplementation is an effective treatment option in major depressive disorder (MDD) associated with chronic low-grade inflammation. EPA is the precursor of specialized pro-resolving lipid mediators (SPMs) termed resolvins (Rv), that serve important roles in the resolution of inflammation. The objective of this study was to assess the effects of different doses of EPA on plasma concentrations of EPA metabolites and SPMs in MDD patients. METHODS: In a 2-site study, 61 MDD patients with body mass index >25 kg/m2 and serum high-sensitivity C-reactive protein ≥3 μg/mL were enrolled in a 12-week randomized trial comparing EPA 1, 2, and 4 g/d to placebo. Plasma EPA (mol%) and SPMs (pg/mL) were measured in 42 study completers at baseline and at the end of treatment by liquid chromatography/mass spectrometry. RESULTS: Plasma EPA and SPM concentrations did not change in the placebo group during 12 weeks of treatment. Plasma EPA and EPA-derived metabolites increased significantly and dose-dependently in all EPA supplementation arms. The increase in 18-hydroxyeicosapentaenoic acid (18-HEPE), the precursor of RvE1-3, was significantly greater with the 4 g/d EPA dose than the other doses from week 4 to 12. RvE1 was undetected in all treatment groups, while RvE2 was detected in half of the subjects both at baseline and after treatment, with dose-dependent increases. RvE3 was detected only after supplementation, dose-dependently. A significant reduction in plasma arachidonic acid (AA), relative to baseline, was observed in all EPA arms. This was in contrast with an increase in AA-derived SPM lipoxin B4 (LXB4) in the 4 g/d arm. CONCLUSIONS: Our results show a robust effect of EPA 4 g/d supplementation in increasing plasma EPA and 18-HEPE levels, associated with improved conversion to RvE2-3, and LXB4 levels.
Authors: Sungwhan F Oh; Maria Dona; Gabrielle Fredman; Sriram Krishnamoorthy; Daniel Irimia; Charles N Serhan Journal: J Immunol Date: 2012-03-26 Impact factor: 5.422
Authors: Thomas Gobbetti; Jesmond Dalli; Romain A Colas; Donata Federici Canova; Marius Aursnes; Delphine Bonnet; Laurent Alric; Nathalie Vergnolle; Celine Deraison; Trond V Hansen; Charles N Serhan; Mauro Perretti Journal: Proc Natl Acad Sci U S A Date: 2017-03-29 Impact factor: 11.205
Authors: Nils Helge Schebb; Annika I Ostermann; Jun Yang; Bruce D Hammock; Andreas Hahn; Jan Philipp Schuchardt Journal: Prostaglandins Other Lipid Mediat Date: 2014-05-29 Impact factor: 3.072
Authors: Jan Philipp Schuchardt; Inga Schneider; Ina Willenberg; Jun Yang; Bruce D Hammock; Andreas Hahn; Nils Helge Schebb Journal: Prostaglandins Other Lipid Mediat Date: 2014-03-22 Impact factor: 3.072
Authors: Katherine M Appleton; Philip D Voyias; Hannah M Sallis; Sarah Dawson; Andrew R Ness; Rachel Churchill; Rachel Perry Journal: Cochrane Database Syst Rev Date: 2021-11-24
Authors: Kimberly Pistorius; Lucy Ly; Patricia R Souza; Esteban A Gomez; Duco S Koenis; Ana R Rodriguez; Julie Foster; Jane Sosabowski; Mark Hopkinson; Vinothini Rajeeve; Bernd W Spur; Andrew Pitsillides; Costantino Pitzalis; Jesmond Dalli Journal: EBioMedicine Date: 2022-04-14 Impact factor: 11.205
Authors: Simon C Dyall; Laurence Balas; Nicolas G Bazan; J Thomas Brenna; Nan Chiang; Felipe da Costa Souza; Jesmond Dalli; Thierry Durand; Jean-Marie Galano; Pamela J Lein; Charles N Serhan; Ameer Y Taha Journal: Prog Lipid Res Date: 2022-05-01 Impact factor: 14.673
Authors: Boadie W Dunlop; Jeffrey J Rakofsky; David Mischoulon; Helen S Mayberg; Becky Kinkead; Andrew A Nierenberg; Thomas R Ziegler; Maurizio Fava; Mark H Rapaport Journal: Pers Med Psychiatry Date: 2022-01-12
Authors: Alessia Costa; Barbara Rani; Thomaz F S Bastiaanssen; Francesco Bonfiglio; Eoin Gunnigle; Gustavo Provensi; Moira Rossitto; Marcus Boehme; Conall Strain; Clara S Martínez; Patrizio Blandina; John F Cryan; Sophie Layé; Renato Corradetti; Maria Beatrice Passani Journal: Int J Mol Sci Date: 2022-01-13 Impact factor: 5.923